Every Form 4 that Versigent PLC (VGNT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow VGNT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VGNT filings page.
Versigent PLC director Kevin P. Clark reported direct sales of 97,278 ordinary shares across five transactions on October 7 and 8, 2026. The reported weighted-average prices were $44.90, $45.68 and $46.43 per share on October 7, and $44.33 and $44.88 on October 8. The sales were made under a Rule 10b5-1 trading plan adopted by Clark on June 3, 2026 through his Kevin P. Clark 2002 Revocable Trust.
Versigent PLC (VGNT) reported that director Amy E. Alving acquired 14.65 Dividend Equivalent Rights on September 18, 2026. These rights accrued on existing restricted stock units due to a dividend declared and paid by Versigent and are each economically equivalent to one ordinary share, vesting on the same schedule as the related restricted stock units.
Versigent PLC (VGNT) director Kevin P. Clark reported an acquisition of 14.65 Dividend Equivalent Rights on September 18, 2026. These derivative rights accrued on prior restricted stock unit grants due to a dividend declared and paid by Versigent and represent the economic equivalent of 14.65 ordinary shares, vesting on the same schedule as the related RSUs.
Versigent PLC (VGNT) reported that Chief People Officer Vinci Sharon acquired 172.634 dividend equivalent rights on September 18, 2026. These rights accrued on previously granted restricted stock units due to a dividend and are economically equivalent to 172.634 ordinary shares, vesting on the same schedule as those units. No Rule 10b5-1 trading plan is reported for this grant.
Versigent PLC (symbol: VGNT) is the issuer of record for a Form 4 filing submitted to the SEC. CELIAN JASON reported acquisition or exercise transactions in this Form 4 filing.
Versigent PLC (ticker VGNT) reported that Chief Accounting Officer Celian Jason received a grant of 25.7530 Dividend Equivalent Rights on September 18, 2026. These derivative rights correspond to 25.7530 ordinary shares, vest on the same schedule as the related restricted stock units, and are held as direct ownership.
Versigent PLC (symbol: VGNT) is the issuer of record for a Form 4 filing submitted to the SEC. Ostermann Douglas R reported acquisition or exercise transactions in this Form 4 filing.
Versigent PLC (VGNT) reported that Chief Financial Officer Ostermann Douglas R received a grant of 480.603 dividend equivalent rights on September 18, 2026. These derivative rights relate to existing restricted stock unit grants and are the economic equivalent of the same number of Versigent ordinary shares.
The dividend equivalent rights accrued because Versigent declared and paid a dividend, and they will vest on the same schedule as the underlying restricted stock units. No Rule 10b5-1 trading plan is indicated for this award, and the CFO’s direct holdings of these rights increased to 480.603 following the transaction.
Versigent PLC (symbol: VGNT) is the issuer of record for a Form 4 filing submitted to the SEC. Liotine Joseph T. reported acquisition or exercise transactions in this Form 4 filing.
Versigent PLC (VGNT) reported that CEO and Director Joseph T. Liotine received an automatic grant of 489.229 dividend equivalent rights on September 18, 2026. These rights accrued on previously granted restricted stock units due to a dividend and are economically equivalent to 489.229 ordinary shares, vesting on the same schedule as the underlying units. No Rule 10b5-1 trading plan is reported.
Versigent PLC (VGNT) director Brad M. Cerepak reported an acquisition of 14.65 Dividend Equivalent Rights on September 18, 2026. These rights accrued on previously granted restricted stock units due to a dividend declared and paid by Versigent and are the economic equivalent of 14.65 ordinary shares, vesting on the same schedule as the related restricted stock units.
Versigent PLC (symbol: VGNT) is the issuer of record for a Form 4 filing submitted to the SEC. Kueppers Eric reported acquisition or exercise transactions in this Form 4 filing.
Versigent PLC (VGNT) reported that director Eric Kueppers received a grant of 14.65 Dividend Equivalent Rights on September 18, 2026. These rights accrued on earlier restricted stock unit grants due to a dividend declared and paid by Versigent and will vest on the same schedule as the related RSUs. Each right is the economic equivalent of one ordinary share.
Versigent PLC (VGNT) reported that director Tamez Armando received a grant of 14.65 Dividend Equivalent Rights on September 18, 2026. These rights accrued on existing restricted stock units due to a dividend declared and paid by Versigent and are the economic equivalent of 14.65 ordinary shares, vesting on the same schedule as the related restricted stock units.
The acquisition is recorded as a derivative award with no cash exercise price and represents a direct holding by the director. No transactions are reported as made under a Rule 10b5-1 trading plan.
Versigent PLC (symbol: VGNT) is the issuer of record for a Form 4 filing submitted to the SEC. MEISTER PAUL M reported acquisition or exercise transactions in this Form 4 filing.
Versigent PLC (VGNT) reported that director Paul M. Meister received a grant of 14.65 Dividend Equivalent Rights on September 18, 2026. These rights accrued on existing restricted stock unit grants following a dividend and are economically equivalent to 14.65 ordinary shares, vesting on the same schedule as the related restricted stock units.
Versigent PLC (symbol: VGNT) is the issuer of record for a Form 4 filing submitted to the SEC. Acosta Janis N reported acquisition or exercise transactions in this Form 4 filing.
Versigent PLC (VGNT) reported that its CLO and Secretary, Janis N. Acosta, received an award of 113.023 dividend equivalent rights on September 18, 2026. These rights accrued on her restricted stock units due to a cash dividend and are the economic equivalent of 113.023 ordinary shares, vesting on the same schedule as the related units. After this award, she directly holds 113.023 dividend equivalent rights, and no Rule 10b5-1 trading plan is reported for this transaction.
Versigent PLC (VGNT) director Kevin P. Clark reported open-market sales of a total of 122,722 Ordinary Shares on September 8–9, 2026, in multiple tranches at weighted average prices between $44.99 and $50.12 per share, as detailed by price ranges in the footnotes.
The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Clark on June 3, 2026 through his Kevin P. Clark 2002 Revocable Trust. The filing does not state Clark’s share holdings after these sales.
Versigent PLC director and CEO Joseph T. Liotine reported a routine share disposition tied to equity compensation. The company withheld 21,289 Ordinary Shares at a price of $45.89 per share to cover tax liabilities when restricted stock units vested. This was not an open-market sale. After the withholding, Liotine directly holds 208,864 Ordinary Shares, indicating he retains a substantial equity stake in Versigent.
CLARK KEVIN P reported acquisition or exercise transactions in this Form 4 filing.
Versigent PLC director Kevin P. Clark reported receiving a grant of 5,168 Ordinary Shares on April 22, 2026, at no cost. After this award, he directly holds 247,571 Ordinary Shares. This total includes 242,403 shares he received on April 1, 2026, in a pro rata distribution from Aptiv PLC.
Vinci Sharon reported acquisition or exercise transactions in this Form 4 filing.
Versigent PLC Chief People Officer Vinci Sharon received a grant of 18,617 Ordinary Shares as compensation. The award was recorded at a price of $0.0000 per share, indicating it was not an open-market purchase. Following this grant, Sharon directly holds a total of 61,474 Ordinary Shares.
Versigent PLC chief legal officer and secretary Janis N. Acosta reported receiving two equity awards of the company’s Ordinary Shares. On April 22, 2026, she acquired 21,254 Ordinary Shares at $0.00 per share in a grant classified as a “grant, award, or other acquisition.” Following this grant, her reported direct holdings in that line were 39,871 shares.
On the same date, she received a second grant of 18,617 Ordinary Shares, also at $0.00 per share, with that line showing 18,617 shares held directly after the transaction. These transactions are compensation-related share awards rather than open‑market purchases or sales.
CELIAN JASON reported acquisition or exercise transactions in this Form 4 filing.
Versigent PLC Chief Accounting Officer Celian Jason received a stock grant of 6,982 Ordinary Shares on April 22, 2026. The award was recorded at a price of $0.0000 per share, indicating a compensation-related grant rather than an open-market purchase. Following this transaction, Jason directly holds 9,335 Ordinary Shares of Versigent PLC.
Versigent PLC reported that its Chief Financial Officer, Douglas R. Ostermann, received a grant of 43,438 Ordinary Shares as a stock award. The shares were acquired at a reported price of $0.00 per share, indicating a compensation-related grant rather than a market purchase.
Following this award, the CFO directly holds 169,542 Ordinary Shares. This filing reflects an equity-based compensation event and does not show any open-market buying or selling activity.
Liotine Joseph T. reported acquisition or exercise transactions in this Form 4 filing.
Versigent PLC disclosed that CEO and director Joseph T. Liotine received a grant of 111,698 Ordinary Shares on April 22, 2026. The award was recorded at a price of $0.00 per share, indicating it is a compensation-related equity grant rather than an open-market purchase. Following this grant, Liotine directly holds 230,153 Ordinary Shares.
Versigent PLC director Brad M. Cerepak received a grant of 5,168 Ordinary Shares as equity compensation. The shares were acquired on a non-cash basis at a reported price of $0.0000 per share. Following this award, he directly holds 5,168 Ordinary Shares, with no derivative positions reported.
Versigent PLC director Eric Kueppers received a grant of 5,168 Ordinary Shares. The shares were acquired on a non-market basis at a reported price of 0.0000 per share, indicating a compensation-related award rather than an open-market purchase. After this grant, his direct holdings total 5,168 Ordinary Shares.
Versigent PLC director Tamez Armando received a share grant reported on Form 4. He was awarded 5,168 Ordinary Shares on April 22, 2026 at a stated price of $0.00 per share, indicating a compensation-related grant rather than an open-market purchase.
After this award, his directly held ownership stands at 5,168 Ordinary Shares. The filing does not show any sales or derivative option exercises, only this single grant/award acquisition transaction.
Versigent PLC director Amy E. Alving received a share grant of 5,168 Ordinary Shares. The award was recorded at a price of $0.00 per share, indicating a compensation-related grant rather than a market purchase. Following this acquisition, she directly holds 5,168 Ordinary Shares.
MEISTER PAUL M reported acquisition or exercise transactions in this Form 4 filing.
Versigent PLC director Paul M. Meister received a stock award of 5,168 Ordinary Shares. The shares were granted at a reported price of $0.00 per share as a compensation-related award, not an open-market purchase or sale.
After this grant, he directly owns 11,561 Ordinary Shares. A footnote notes that his holdings include 6,393 Versigent Ordinary Shares previously received in a pro rata distribution from Aptiv PLC completed on April 1, 2026.
Versigent PLC Chief People Officer Vinci Sharon reported an equity grant related to Versigent’s separation from Aptiv PLC. On April 2, 2026, Sharon acquired 42,283 ordinary shares at a stated price of $0.00 per share through converted restricted stock unit awards.
Following this grant and the earlier pro rata distribution of Versigent shares to Aptiv shareholders, Sharon now holds 42,857 Versigent ordinary shares directly. The award reflects the conversion of prior Aptiv restricted stock units into Versigent awards under long-term incentive and employee matters agreements.
Versigent PLC Chief Financial Officer Ostermann Douglas R received 126,104 ordinary shares or related share-based awards. The Form 4 shows a grant or award acquisition at a price of $0.00 per share, leaving him with 126,104 ordinary shares held directly after the transaction.
According to the footnotes, these Issuer RSU Awards arose from the conversion of prior Aptiv PLC restricted stock unit awards and include Versigent ordinary shares received in Aptiv’s pro rata distribution of all Versigent shares to Aptiv shareholders.
Versigent PLC Chief Accounting Officer Celian Jason reported an equity compensation grant on a Form 4. He acquired 2,103 ordinary shares of Versigent at a price of $0.00 per share, increasing his direct holdings to 2,353 ordinary shares after the transaction.
According to the footnotes, these shares reflect restricted stock unit awards that were converted from prior Aptiv PLC RSU awards in connection with Aptiv’s pro rata distribution of Versigent shares and are subject to Versigent’s 2026 Long-Term Incentive Plan terms and vesting conditions.
Versigent PLC director and Chief Executive Officer Joseph T. Liotine reported an acquisition of 109,714 ordinary shares on April 2, 2026. These shares represent restricted stock unit awards that were converted from prior Aptiv PLC awards in connection with Aptiv’s pro rata distribution of Versigent shares.
After this equity grant and related distribution, Liotine directly holds 118,455 Versigent ordinary shares. The Issuer RSU awards are governed by the Versigent PLC 2026 Long-Term Incentive Plan and generally keep the same vesting conditions and other restrictions that applied to the original Aptiv restricted stock unit awards.